Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Lopez Rodriguez (Hannover, Germany), C. Laukamp (Hannover, Germany), L. Steffen (Hannover, Germany), M. Ochs (Hannover, Germany), L. Knudsen (Hannover, Germany). Pulmonary surfactant as drug delivery system to target lung epithelium: new approach for the treatment of epithelial injury after bleomycin challenge. 592

Member's Comments

No comment yet.

Related content which might interest you: An evaluation of the potential for inhaled xenobiotics to develop cancer in the lung using a 3D in vitro model of the human epithelial airway-wall Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 A human lung reperfusion model for monitoring the initial pulmonary absorption of drugs from aerosol devices Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005 Transgenic mice expressing a surfactant protein-B-urokinase-fusion protein in the distal respiratory epithelium show an attenuated fibrotic response to bleomycin-induced lung injury Source: Annual Congress 2005 - In vivo - approaches to lung injury Year: 2005 Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments Year: 2018 Translocation of TNF-α from the gut to the lung by VILI is reduced by exogenous surfactant therapy Source: Eur Respir J 2002; 20: Suppl. 38, 375s Year: 2002 Interferon-? liposome: a new system to improve drug delivery in the treatment of lung cancer Source: ERJ Open Res, 7 (3) 00555-2020; 10.1183/23120541.00555-2020 Year: 2021 The effects of erdosteine and N-acetylcysteine treatment following lung injury on the regulation of apoptosis of capillary endothelial cells in the model of experimental pulmonary fibrosis induced by bleomycin Source: Annual Congress 2008 - Airway cell biology and immunology Year: 2008 What the pulmonary specialist should know about the new inhalation therapies Source: Eur Respir J 2011; 37: 1308-1417 Year: 2011 Nanoparticle-assisted gene delivery in a bleomycin-injured lung fibrosis model Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Oral presentation: Human lung parenchyma cells: a potential therapeutic cell source for lung disease Source: Lung Science Conference 2009 - Cell proliferation, Differentiation and Carcinogenesis Year: 2009 TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells Source: Virtual Congress 2021 – Emerging respiratory diseases: state-of-the-art studies of SARS-CoV-2 infection Year: 2021 New nebulized treatment options for bronchial infection in lung transplant Source: Virtual Congress 2020 – Clinical management of lung transplant recipients Year: 2020 A novel approach for optimal lung recruitment in acute lung injury Source: Annual Congress 2005 - Pulmonary function outcome, respiratory morbidity in prematurely born children and acute lung injury Year: 2005 Combined application of lung recruitment maneuver and surfactant administration for the treatment of ARDS after operation on heart Source: Annual Congress 2008 - Acute lung injury and weaning Year: 2008 Late Breaking Abstract - Spatial pharmacokinetics of inhaled drugs in human lung – evaluation of regional lung targeting by direct sampling of epithelial lining fluid Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 When to start surfactant therapy (ST-therapy) of acute lung injury? Source: Eur Respir J 2001; 18: Suppl. 33, 7s Year: 2001 The pIgR-IgA system as a new player in lung fibrosis Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 The use of alveolar epithelial type I cell-selective markers to investigate lung injury and repair Source: Eur Respir J 2004; 24 : 664-673 Year: 2004 The histopathalogical evaluation of administration route of bleomycin in pulmonary fibrosis model and contribution of smoking to development of fibrosis Source: Annual Congress 2007 - Pathogenesis of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis Year: 2007